In recent years, health policy pushes have seen an increasing focus on drug costs. Proposals have embraced concepts like price referencing, transparency requirements, and drug importation. In this report, I examine congressional legislation and commercial payer positions on these approaches. The data reveal little opposition to policies such as international reference pricing or drug importation.
Neumann U. (2020). The Escalating US Policy Environment. Payer Views on Current Drug Pricing Proposals. Certara.